



Out of the shadows of depression  
and phobia with

**Anafranil®**  
(clomipramine hydrochloride)

**Geigy**

Anafranil (clomipramine hydrochloride). Dosage: Depression – 30–50mg per day. In severe cases increase to 75mg or higher if necessary. Phobic/Obsessional States – generally higher dosage – build up to 100–150mg per day. Contra-indications: 1) Anafranil is contra-indicated in conjunction with, or within 14 days of treatment with a monoamine oxidase inhibitor. 2) In existing liver damage. 3) In cardiac/circulatory failure or following a recent myocardial infarction. Precautions: Caution is necessary in ischaemic heart disease, glaucoma, and retention of urine. Great caution in patients with epilepsy. Anafranil may antagonise the action of certain antihypertensive drugs, and may potentiate the cardiovascular action of noradrenaline and adrenaline. As with other drugs, avoid using during the first trimester of pregnancy if possible. Side effects: Dry mouth, sweating, difficulty with accommodation, constipation, disturbance of micturition, tachycardia. Less commonly tremor, ataxia, orthostatic hypotension and vertigo. More rarely anxiety, agitation, fatigue, drowsiness, confusion, insomnia and headache. Epileptiform seizures have occurred in a small number of patients. Symptomless hypothermia and allergic skin reactions are extremely rare. Interference with sexual function, particularly ejaculation, may be encountered. Agranulocytosis has occasionally occurred in patients on tricyclic antidepressants – routine blood counts are advised during treatment with Anafranil. Availability: Two-tone yellow/caramel capsules of 10mg (PL 0001/0037) £3.10 per 100. Two-tone orange/caramel capsules of 25mg (PL 0001/5000) £6.11 per 100. Two-tone blue/caramel capsules of 50mg (PL 0001/0068) £11.63 per 100. Orange flavoured and coloured syrup containing 25mg of Anafranil in 5ml (PL 0001/5001) £5.55 per 150ml bottle. Full prescribing information is available on request from Geigy Pharmaceuticals, Horsham, West Sussex.

## NOTES FOR CONTRIBUTORS

**PAPERS** Papers for publication should be addressed to the Editor, Professor Michael Shepherd, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF. Contributors should send at least three copies of the text, tables, and figures. Copies other than the first may be xeroxed. The S.I. system should be adopted for text and figures. A short synopsis of about 50 words should be provided at the beginning of each article. Foreign quotations and phrases should be followed by a translation. Submission of a paper will be held to imply that it contains original work that has not been previously published and that it is not being submitted for publication elsewhere.

In addition to longer articles, the Editor is prepared to accept preliminary communications of between 1500 and 2000 words.

Manuscripts must be typewritten on one side of the paper in double-spacing with wide margins. The following information must be given on a single separate sheet: (1) title and short title for running head (not more than 100 characters); (2) authors' names, and (3) department in which work was done. Footnotes on the same sheet should list: (i) the authors' present addresses if different from departments in which work was done; (ii) name and address of the author to whom correspondence should be addressed; (iii) receipt of grants. Authors who would like a reprint address to be printed should include this on their manuscript.

**REFERENCES** (1) In the text these should follow the Harvard system – that is, name followed by date: Brown (1970). If there are more than two authors the first author's name followed by *et al.* should be used, even the first time that the reference appears. (2) The list of references should be typed in alphabetical order on a separate sheet and should appear as follows: Brown, J., Williams, E. & Wright, H. (1970). Treatment of heroin addiction. *Psychological Medicine* 1, 134–136. Journal titles should be given in full.

Books should be cited as follows: Brown, J. (1970). *Psychiatric Research*. Smith: Glasgow.

**ILLUSTRATIONS** Only essential figures and tables should be included. *Photographs* Unmounted photographs on glossy paper should be provided. Magnification scales, if necessary, should be lettered on these. Where possible, prints should be trimmed to column width (i.e. 70 mm). *Diagrams* These will usually be reduced to 70 mm wide. Lettering should be in either Letraset or stencil, and care should be taken that lettering and symbols are of comparable size. Illustrations should not be inserted in the text, they should be marked on the back with figure numbers, title of paper, and name of author. All photographs, graphs, and diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet. *Tables* Tables should be numbered consecutively in the text in Arabic numerals and each typed on a separate sheet.

**PROOFS AND OFFPRINTS** Page proofs will be sent to the senior author. Corrections other than printer's errors may be charged to the author. Fifty offprints of each paper are supplied free; additional offprints are available according to a scale of charges if they are ordered when the proof is returned.

# Psychological Medicine

Volume 10 Number 1 February 1980

## CONTENTS

### EDITORIALS

Choline, acetylcholine and dementia	page 1
Methodological issues in psychiatric case-identification	5
Whence and whither 'liaison' psychiatry?	11
<b>SMITH, R.</b>	
Scientific thought and the boundary of insanity and criminal responsibility	15
<b>SHEPHERD, M.</b>	
Psychotropic drugs and taxonomic systems	25
<b>CHECKLEY, S. A.</b>	
Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness	35
<b>MARSDEN, C. D. AND JENNER, P.</b>	
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs	55
<b>BROCKINGTON, I. F., WAINWRIGHT, S. AND KENDELL, R. E.</b>	
Manic patients with schizophrenic or paranoid symptoms	73
<b>WOLFF, S. AND CHICK, J.</b>	
Schizoid personality in childhood: a controlled follow-up study	85
<b>WILLIAMS, P., TARNOPOLSKY, A. AND HAND, D.</b>	
Case definition and case identification in psychiatric epidemiology: review and assessment	101
<b>COCHRANE, R.</b>	
A comparative evaluation of the Symptom Rating Test and the Langner 22-item Index for use in epidemiological surveys	115
<b>DEPAULO, J. R., FOLSTEIN, M. F. AND GORDON, B.</b>	
Psychiatric screening on a neurological ward	125
<b>BRUDER, G., SPRING, B., YOZAWITZ, A. AND SUTTON, S.</b>	
Auditory sensitivity in psychiatric patients and non-patients: monotonic click detection	133
<b>CATTS, S. V., ARMSTRONG, M. S., NORCROSS, K. AND MCCONAGHY, N.</b>	
Auditory hallucinations and the Verbal Transformation Effect	139
<b>JOHNSTON, M.</b>	
Anxiety in surgical patients	145
<b>POLL, I. B. AND KAPLAN DE-NOUR, A.</b>	
Locus of control and adjustment to chronic haemodialysis	153
<b>GARDINER, B. M.</b>	
Psychological aspects of rheumatoid arthritis	159
<b>SNOWDON, J.</b>	
A comparison of written and postbox forms of the Leyton Obsessional Inventory	165
<b>BRIEF COMMUNICATION</b>	
Awareness of cardiac function in anxious, phobic and hypochondriacal patients	
<b>P. TYRER, I. LEE AND J. ALEXANDER</b>	171
<b>RESEARCH REPORT</b>	
The research component of the WHO mental health programme	175
<b>BOOK REVIEWS</b>	187

© Cambridge University Press 1980

CAMBRIDGE UNIVERSITY PRESS

The Pitt Building, Trumpington Street, Cambridge CB2 1RP

32 East 57th Street, New York, N.Y. 10022

Printed in Great Britain at the University Press, Cambridge